← All organizations
Highest phase reached
Phase 4
First clinical trial
Aug 1, 2007Last known activity
Mar 22, 2025
Timeline
1990s
- Jan 1, 1994
TFS Trial Form Support— Founded
2010s
- Jun 18, 2015
ViroXis Corporation— Acquired
- Oct 11, 2016
Sciderm GmbH— Acquired
Drugs by trial phase (40 distinct, 31 trials)
Phase 4 (2 own, 0 via acquisition)
Phase 3 (6 own, 1 via acquisition)
Phase 2 (21 own, 7 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Studied for
- Amyotrophic Lateral Sclerosis
- Carcinoma
- Carcinoma, Renal Cell
- Colorectal Neoplasms
- Conjunctivitis
- Conjunctivitis, Viral
- Crohn Disease
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Heart Failure
- Inflammation
- Keratoconjunctivitis
- Macular Degeneration
- Motor Neuron Disease
- Mucositis
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Obesity
- Parkinson Disease
- Prostatic Neoplasms
- Psoriasis
- Spondylolisthesis
- Wet Macular Degeneration
Subsidiaries (2 direct, 3 total across the full acquisition tree)
Recent trials (20)
- NCT06690710CollaboratorPhase 1Mar 22, 2025
- NCT05357989CollaboratorPhase 3Aug 3, 2022
- NCT05222724CollaboratorPhase 4Oct 26, 2021
- NCT04778176CollaboratorPhase 2Jun 16, 2021
- NCT04247256CollaboratorPhase 1/Phase 2Feb 29, 2020
- NCT03751007CollaboratorPhase 1/Phase 2Oct 27, 2018
- NCT03591887CollaboratorPhase 2Mar 7, 2018
- NCT07017114CollaboratorPhase 1Jan 27, 2016
- NCT02656329CollaboratorPhase 3Jan 1, 2016
- NCT02448914CollaboratorPhase 1May 1, 2015
- NCT02432846CollaboratorPhase 2Apr 1, 2015
- NCT01951924CollaboratorPhase 3Dec 1, 2013
- NCT01977443CollaboratorPhase 2Nov 1, 2013
- NCT01896284CollaboratorPhase 4Jul 1, 2013
- NCT01562951CollaboratorPhase 3Oct 1, 2012
Details
- Founded
- Lund, SE Jan 1, 1994
- Last known activity
- Mar 22, 2025